ArticleEpilepsy currents2021
Treatment of Super-Refractory Status Epilepticus: A Review.
Article in Epilepsy currents, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Surgical Interventions for Super-Refractory Status Epilepticus: A Systematic Review.Neurocritical care · 2026Pooled it
- Surgical management of status epilepticus: A systematic review.Epilepsia open · 2024Pooled it
- Acute symptomatic seizures after accidental intrathecal lidocaine administration: A case series.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Lesionectomy as management for super-refractory status epilepticus due to focal cortical dysplasia: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Successful application of vagus nerve stimulation in super refractory status epilepticus associated with MERRF syndrome.Epilepsy & behavior reports · 2025Article
- Effectiveness of Highly Purified Cannabidiol in Refractory and Super-Refractory Status Epilepticus: A Case Series.CNS & neurological disorders drug targets · 2025Article
- Cerebrospinal fluid and serum cytokine profiles in severe viral encephalitis with implications for refractory status epilepticus: a retrospective observational study.Frontiers in immunology · 2025Observational
- Treatment of convulsive status epilepticus in Brazil: a review.Arquivos de neuro-psiquiatria · 2025Review
- The Fundamentals of Antiseizure Medications: A Through Z.Epilepsy currents · 2024Article
- Super Refractory Status Epilepticus Improved After Emergency Use of Ganaxolone: Case Report.The Neurohospitalist · 2024Article
- Hydrogen treatment reduces electroencephalographic activity and neuronal death in rats with refractory status epilepticus by inhibiting membrane NR2B phosphorylation and oxidative stress.The Journal of international medical research · 2024Article
- Role of Vagus Nerve Stimulation in Refractory and Super Refractory Status Epilepticus: A Pediatric Case Series.Brain sciences · 2023Article
- Pediatric Status Epilepticus: Treat Early and Avoid Delays.Paediatric drugs · 2023Review
- Evaluating salvage electroconvulsive therapy for the treatment of prolonged super refractory status epilepticus: A case series.Epilepsy & behavior : E&B · 2023Article
- Effect of vagus nerve stimulation against generalized seizure and status epilepticus recurrence.Frontiers in neurology · 2023Article
- Lidocaine as a potential therapeutic option for super-refractory status epilepticus: A case report.Journal of central nervous system disease · 2023Article
- A New Non-invasive Neuromodulation Technique for Super Refractory Status Epilepticus: Can We Consider tDCS for This Devastating Condition?Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Article
- Super-refractory status epilepticus in adults.Neurological research and practice · 2022Article
- Factors associated with mortality in patients with super-refractory status epilepticus.Scientific reports · 2022Article
- Dogs as a Natural Animal Model of Epilepsy.Frontiers in veterinary science · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSuper-refractory status epilepticus (SRSE) presents management challenges due to the absence of randomized controlled trials and a plethora of potential medical therapies. The literature on treatment options for SRSE reports variable success and quality of evidence. This review is a sequel to the 2020 American Epilepsy Society (AES) comprehensive review of the treatment of convulsive refractory status epilepticus (RSE).
methodsWe sought to determine the effectiveness of treatment options for SRSE. We performed a structured literature search (MEDLINE, Embase, CENTRAL, CINAHL) for studies on reported treatments of SRSE. We excluded antiseizure medications (ASMs) covered in the 2016 AES guideline on the treatment of established SE and the convulsive RSE comprehensive review of the 2020 AES. Literature was reviewed on the effectiveness of vagus nerve stimulation, ketogenic diet (KD), lidocaine, inhalation anesthetics, brain surgery, therapeutic hypothermia, perampanel, pregabalin (PGB), and topiramate in the treatment of SRSE. Two authors reviewed each therapeutic intervention. We graded the level of the evidence according to the 2017 classification scheme of the American Academy of Neurology.
resultsFor SRSE (level U; 39 class IV studies total), insufficient evidence exists to support that perampanel, PGB, lidocaine, or acute vagus nerve stimulation (VNS) is effective. For children and adults with SRSE, insufficient evidence exists to support that the KD is effective (level U; 5 class IV studies). For adults with SRSE, insufficient evidence exists that brain surgery is effective (level U, 7 class IV studies). For adults with SRSE insufficient, evidence exists that therapeutic hypothermia is effective (level C, 1 class II and 4 class IV studies). For neonates with hypoxic-ischemic encephalopathy, insufficient evidence exists that therapeutic hypothermia reduces seizure burden (level U; 1 class IV study). For adults with SRSE, insufficient evidence exists that inhalation anesthetics are effective (level U, 1 class IV study) and that there is a potential risk of neurotoxicity.
conclusionFor patients with SRSE insufficient, evidence exists that any of the ASMs reviewed, inhalational anesthetics, ketogenic diet, acute VNS, brain surgery, and therapeutic hypothermia are effective treatments. Data supporting the use of these treatments for SRSE are scarce and limited mainly to small case series and case reports and are confounded by differences in patients' population, and comedications, among other factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.